CAMKV kinase drives #neuroblastoma growth and acts as a novel therapeutic target. New study from Yang Yu, Yanling Zhao, Zhongcheng Shi, Larry L. Wang, Chunchao Zhang, Jianhua Yang @childrensnational.bsky.social and colleagues:
rupress.org/jem/article/...

#SolidTumors

Nahuel Ko and colleagues propose that #TissueResidency should be incorporated into next-generation #Immunotherapy to achieve durable responses in #SolidTumors

#Hypoxia enhances EnAd oncolytic activity via HIF-2α/HIF-1β-mediated activation of an E1A promoter HRE, revealing how tumor microenvironments drive viral replication and inform #Adenovirus-based therapies for #SolidTumors. @ox.ac.uk

#STTT #OpenAccess: doi.org/10.1038/s413...

#TumorHeterogeneity and #Immunosuppressive microenvironments hinder the treatment of #SolidTumors.

This review explores diverse immune and stem-cell platforms, alongside allogeneic and in vivo engineering strategies for broader cancer treatment.

#STTT #OpenAccess: doi.org/10.1038/s413...

Limited efficacy constrains #HDAC inhibitors in #SolidTumors.

Nuclear PFKL inhibits class I HDACs and potentiates romidepsin through Thr562, guiding the development of a PFKL-derived peptide that enhances antitumor activity.

#STTT #OpenAccess: doi.org/10.1038/s413...

Is #JAKSTAT a friend or foe in #SolidTumors?
This review reveals paradoxical roles, showing how direct inhibition fuels immune exhaustion and resistance, and proposes system‑level targeting to overcome the impasse.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...